<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02810327</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00036911</org_study_id>
    <nct_id>NCT02810327</nct_id>
  </id_info>
  <brief_title>Alpha-1 Carrier Genomics Study</brief_title>
  <official_title>Alpha-1 Carrier Genomics Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of South Carolina</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CSL Behring</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical University of South Carolina</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this study is to better understand why some Alpha-1 genotype MZ (PiMZ)
      individuals develop chronic obstructive pulmonary disease (COPD) while others do not. This
      study will examine portions of the Alpha-1 gene that are not routinely tested to determine
      whether other changes in this gene correlate with development and progression of COPD.
      Participation involves responding to questionnaires about lung health and history, and
      performing an at-home finger stick to obtain blood spots using a test kit that is mailed. The
      blood provided will be used for genetic testing and correlation of results with COPD history.
      Participants will receive their results and access to genetic counseling at the conclusion of
      the study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Alpha-1 Antitrypsin Deficiency (AATD, Alpha-1) is the best established genetic risk factor
      for chronic obstructive pulmonary disease (COPD) and liver disease. Clinical presentation is
      heterogeneous in most genotypic populations of alpha-1 antitrypsin deficiency (AATD) and
      genetic variation in the Alpha-1 gene has been incompletely studied. Rare gene alterations
      that predispose to COPD risks of classic AATD in individuals without a classic homozygous
      deficiency genotype have not been studied and are important in understanding, testing and
      treating at-risk populations. Investigators hypothesize that SERPINA1 gene sequencing will
      find important sequence variations in previously assessed MZ individuals who have COPD
      compared to age, race, sex, AAT level and smoking status matched MZ individuals who do not
      have COPD.

      The Alpha-1 Carrier Genomics study is a pilot study that will enroll up to 150 MZ
      individuals. COPD+ and COPD- individuals will be matched on age, sex, race and smoking
      history. Presence and severity of COPD is assessed by a COPD severity score on
      questionnaires. Participants will be mailed a test kit to obtain and return a blood sample by
      finger stick for the purpose of SERPINA1 gene sequencing. Gene sequencing will identify, if
      present, genomic signatures that may correlate with COPD in this cohort. Participants will
      receive their results and access to genetic counseling at the conclusion of this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 2015</start_date>
  <completion_date type="Actual">April 2017</completion_date>
  <primary_completion_date type="Actual">April 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Abnormal Sequences in SERPINA1 Genes</measure>
    <time_frame>End of study NGS Result</time_frame>
    <description>Additional SERPINA1 variant of known or possible significance detected by next generation sequencing.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">117</enrollment>
  <condition>Alpha-1 Antitrypsin Deficiency</condition>
  <condition>Emphysema</condition>
  <condition>COPD</condition>
  <condition>Smoking</condition>
  <arm_group>
    <arm_group_label>MZ heterozygote with symptoms of COPD</arm_group_label>
    <description>Individuals who have previously had testing for Alpha-1 antitrypsin deficiency with genotype MZ (PiMZ) results. Individuals in this cohort have symptoms or clinical diagnosis of COPD.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MZ heterozygote without symptoms of COPD</arm_group_label>
    <description>Individuals who have previously had testing for Alpha-1 antitrypsin deficiency with genotype MZ (PiMZ) results. Individuals in this cohort do not have symptoms or clinical diagnosis of COPD.</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Genetic Sequencing</intervention_name>
    <description>Sequencing of the SERPINA1 gene</description>
    <arm_group_label>MZ heterozygote with symptoms of COPD</arm_group_label>
    <arm_group_label>MZ heterozygote without symptoms of COPD</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Bloodspot collections for DNA and limited protein analysis
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Individuals age 18 and over who have previously had testing for Alpha-1 antitrypsin
        deficiency with genotype MZ (PiMZ) results, and an alpha-1 antitrypsin level of less than
        16.0uM (83mg/dL) are eligible to participate.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Signed informed consent

          2. PiMZ individuals who fall into the lower quartile of AAT levels.

        Exclusion Criteria:

          1. Age &lt;18 years

          2. Known homozygous or compound heterozygous classic severe AATD (e.g. PiSZ, ZZ, Znull)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charlie Strange, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of South Carolina</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical University of South Carolina. Division of Pulmonary and Critical Care Medicine</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Demeo DL, Sandhaus RA, Barker AF, Brantly ML, Eden E, McElvaney NG, Rennard S, Burchard E, Stocks JM, Stoller JK, Strange C, Turino GM, Campbell EJ, Silverman EK. Determinants of airflow obstruction in severe alpha-1-antitrypsin deficiency. Thorax. 2007 Sep;62(9):806-13. Epub 2007 Mar 27.</citation>
    <PMID>17389752</PMID>
  </reference>
  <reference>
    <citation>Molloy K, Hersh CP, Morris VB, Carroll TP, O'Connor CA, Lasky-Su JA, Greene CM, O'Neill SJ, Silverman EK, McElvaney NG. Clarification of the risk of chronic obstructive pulmonary disease in Î±1-antitrypsin deficiency PiMZ heterozygotes. Am J Respir Crit Care Med. 2014 Feb 15;189(4):419-27. doi: 10.1164/rccm.201311-1984OC.</citation>
    <PMID>24428606</PMID>
  </reference>
  <reference>
    <citation>Eisner MD, Trupin L, Katz PP, Yelin EH, Earnest G, Balmes J, Blanc PD. Development and validation of a survey-based COPD severity score. Chest. 2005 Jun;127(6):1890-7.</citation>
    <PMID>15947299</PMID>
  </reference>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>June 20, 2016</study_first_submitted>
  <study_first_submitted_qc>June 21, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 22, 2016</study_first_posted>
  <results_first_submitted>August 1, 2018</results_first_submitted>
  <results_first_submitted_qc>May 20, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">July 22, 2019</results_first_posted>
  <last_update_submitted>May 20, 2019</last_update_submitted>
  <last_update_submitted_qc>May 20, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 22, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Alpha-1 antitrypsin deficiency</keyword>
  <keyword>AATD</keyword>
  <keyword>Alpha-1</keyword>
  <keyword>SERPINA1</keyword>
  <keyword>MZ</keyword>
  <keyword>Carrier</keyword>
  <keyword>Heterozygote</keyword>
  <keyword>Smoking</keyword>
  <keyword>COPD</keyword>
  <keyword>Emphysema</keyword>
  <keyword>Sequencing</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alpha 1-Antitrypsin Deficiency</mesh_term>
    <mesh_term>Pulmonary Emphysema</mesh_term>
    <mesh_term>Emphysema</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>April 1, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/27/NCT02810327/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>May 12, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/27/NCT02810327/ICF_001.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 1, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/27/NCT02810327/SAP_002.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>MZ Heterozygote With Symptoms of COPD</title>
          <description>Individuals who have previously had testing for Alpha-1 antitrypsin deficiency with genotype MZ (PiMZ) results. Individuals in this cohort have symptoms or clinical diagnosis of COPD.
Genetic Sequencing: Sequencing of the SERPINA1 gene</description>
        </group>
        <group group_id="P2">
          <title>MZ Heterozygote Without Symptoms of COPD</title>
          <description>Individuals who have previously had testing for Alpha-1 antitrypsin deficiency with genotype MZ (PiMZ) results. Individuals in this cohort do not have symptoms or clinical diagnosis of COPD.
Genetic Sequencing: Sequencing of the SERPINA1 gene</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="76"/>
                <participants group_id="P2" count="41"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="69"/>
                <participants group_id="P2" count="34"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Individuals age 18 and over with previous MZ results for Alpha-1 antitrypsin deficiency and AAT level in the lower MZ quartile (&lt;16uM).</population>
      <group_list>
        <group group_id="B1">
          <title>MZ Heterozygote With Symptoms of COPD</title>
          <description>Individuals who have previously had testing for Alpha-1 antitrypsin deficiency with genotype MZ (PiMZ) results. Individuals in this cohort have symptoms or clinical diagnosis of COPD.
Genetic Sequencing: Sequencing of the SERPINA1 gene</description>
        </group>
        <group group_id="B2">
          <title>MZ Heterozygote Without Symptoms of COPD</title>
          <description>Individuals who have previously had testing for Alpha-1 antitrypsin deficiency with genotype MZ (PiMZ) results. Individuals in this cohort do not have symptoms or clinical diagnosis of COPD.
Genetic Sequencing: Sequencing of the SERPINA1 gene</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="76"/>
            <count group_id="B2" value="41"/>
            <count group_id="B3" value="117"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <population>14 consented participants did not return their test kits and/or questionnaires.</population>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <title>Age</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="69"/>
                    <count group_id="B2" value="34"/>
                    <count group_id="B3" value="103"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51.7" lower_limit="18" upper_limit="73"/>
                    <measurement group_id="B2" value="52.8" lower_limit="29" upper_limit="70"/>
                    <measurement group_id="B3" value="52" lower_limit="18" upper_limit="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <population>14 consented participants did not return their test kits and/or questionnaires.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="69"/>
                    <count group_id="B2" value="34"/>
                    <count group_id="B3" value="103"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="78"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <population>14 consented participants did not return their test kits and/or questionnaires.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="69"/>
                    <count group_id="B2" value="34"/>
                    <count group_id="B3" value="103"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="68"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="102"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Abnormal Sequences in SERPINA1 Genes</title>
        <description>Additional SERPINA1 variant of known or possible significance detected by next generation sequencing.</description>
        <time_frame>End of study NGS Result</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MZ Heterozygote With Symptoms of COPD</title>
            <description>Individuals who have previously had testing for Alpha-1 antitrypsin deficiency with genotype MZ (PiMZ) results. Individuals in this cohort have symptoms or clinical diagnosis of COPD.
Genetic Sequencing: Sequencing of the SERPINA1 gene</description>
          </group>
          <group group_id="O2">
            <title>MZ Heterozygote Without Symptoms of COPD</title>
            <description>Individuals who have previously had testing for Alpha-1 antitrypsin deficiency with genotype MZ (PiMZ) results. Individuals in this cohort do not have symptoms or clinical diagnosis of COPD.
Genetic Sequencing: Sequencing of the SERPINA1 gene</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Abnormal Sequences in SERPINA1 Genes</title>
          <description>Additional SERPINA1 variant of known or possible significance detected by next generation sequencing.</description>
          <units>participants</units>
          <param>Number</param>
          <units_analyzed>samples</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>samples</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The MUSC Bioinformatics Core analyzed group genomic data for variant association with COPD severity score, including single variant association or type of variant association with symptoms. Descriptive statistical analysis was performed using statistical package SAS 9.4 for Windows (SAS Institute Inc., Cary, NC, USA).</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.054</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year, 1 month</time_frame>
      <group_list>
        <group group_id="E1">
          <title>MZ Heterozygote With Symptoms of COPD</title>
          <description>Individuals who have previously had testing for Alpha-1 antitrypsin deficiency with genotype MZ (PiMZ) results. Individuals in this cohort have symptoms or clinical diagnosis of COPD.
Genetic Sequencing: Sequencing of the SERPINA1 gene</description>
        </group>
        <group group_id="E2">
          <title>MZ Heterozygote Without Symptoms of COPD</title>
          <description>Individuals who have previously had testing for Alpha-1 antitrypsin deficiency with genotype MZ (PiMZ) results. Individuals in this cohort do not have symptoms or clinical diagnosis of COPD.
Genetic Sequencing: Sequencing of the SERPINA1 gene</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Kimberly Brown Foil</name_or_title>
      <organization>Medical University of South Carolina</organization>
      <phone>843-792-6474</phone>
      <email>foilk@musc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

